← Back to Search

Contrast Agent

Cardiac Magnetic Resonance study for Dilated Cardiomyopathy

N/A
Waitlist Available
Led By Oliver Strohm, MD, FESC
Research Sponsored by Oliver Strohm
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Different studies have shown that fibrosis of the heart increases the risk for a sudden death from e.g. arrhythmias. Magnetic Resonance Imaging (CMR) can easily identify even small areas of fibrosis in the heart muscle after contrast agent application (Gadolinium). With the development of faster scanners and new contrast agents, the detection of small fibrotic areas may even be improved. In this study, we will apply dedicated T1- and T2-weighted CMR sequences before and after administration of Gadolinium-based contrast (Gadobutrol, Gadovist(r)), the study parameters will be full cardiac function, areas of edema, areas of inflammation and areas of fibrosis. We hypothesize, that we can detect fibrotic areas in the myocardium using Gadobutrol (Gadovist (r)) better than with the commonly used Gadolinium-DTPA contrast agents. We also hypothesize, that fibrosis of the myocardium is correlated to prognosis of the patients.

Eligible Conditions
  • Dilated Cardiomyopathy
  • Cardiomyopathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Active Control
Group I: A1Active Control1 Intervention
CMR study for the assessment of irreversible tissue damage

Find a Location

Who is running the clinical trial?

Oliver StrohmLead Sponsor
BayerIndustry Sponsor
2,275 Previous Clinical Trials
25,539,359 Total Patients Enrolled
Oliver Strohm, MD, FESCPrincipal InvestigatorUniversity of Calgary
2 Previous Clinical Trials
166 Total Patients Enrolled
~2 spots leftby Dec 2025